Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation
Open Access
- 1 October 2016
- journal article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 16 (1), 24-29
- https://doi.org/10.1016/j.jcf.2016.09.005
Abstract
No abstract availableKeywords
Funding Information
- NIH (P30 DK072482)
- Emily's Entourage LLC
- Cystic Fibrosis Foundation
This publication has 21 references indexed in Scilit:
- Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense MutationsAmerican Journal of Respiratory and Critical Care Medicine, 2016
- Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With IvacaftorClinical Infectious Diseases, 2014
- Synthetic Aminoglycosides Efficiently Suppress Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations and Are Enhanced by IvacaftorAmerican Journal of Respiratory Cell and Molecular Biology, 2014
- Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54Journal of Molecular Medicine, 2011
- Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutationNew England Journal of Medicine, 2010
- Restoration of W1282X CFTR Activity by Enhanced ExpressionAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- In vitroprediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot studyBMC Medicine, 2007
- Evidence that Systemic Gentamicin Suppresses Premature Stop Mutations in Patients with Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2001
- A Pilot Study of the Effect of Gentamicin on Nasal Potential Difference Measurements in Cystic Fibrosis Patients Carrying Stop MutationsAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosisCell, 1993